Johnson & Johnson (JNJ) Expected to Announce Quarterly Earnings on Tuesday

Johnson & Johnson (NYSE:JNJ - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Tuesday, April 15th. Analysts expect the company to announce earnings of $2.59 per share and revenue of $21.65 billion for the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.500-10.700 EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Trading Down 0.7 %

Shares of JNJ stock traded down $1.01 on Wednesday, reaching $152.61. 824,837 shares of the stock were exchanged, compared to its average volume of 9,829,637. The stock has a market cap of $367.77 billion, a PE ratio of 22.95, a P/E/G ratio of 2.56 and a beta of 0.49. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a 50 day moving average price of $159.39 and a 200 day moving average price of $155.10.

Remove Ads

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.41%. Johnson & Johnson's payout ratio is presently 74.59%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on JNJ shares. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Argus raised Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Leerink Partners dropped their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Bank of America dropped their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Finally, Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Eight research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $171.50.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Institutional Trading of Johnson & Johnson

A hedge fund recently raised its stake in Johnson & Johnson stock. Brighton Jones LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,876 shares of the company's stock after purchasing an additional 6,332 shares during the quarter. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 at the end of the most recent reporting period. Institutional investors own 69.55% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.